×

Biotech and Pharmaceuticals Pharmaceuticals

  • What to watch at ASCO cancer conference

    CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.

  • Here's what the latest data on cancer research means for biotech stocks

    CNBC's Meg Tirrell reports on the drug stocks reacting to the data dump. The "Fast Money" traders weigh in.

  • Jeff Bezos

    Robert Willoughby, Credit Suisse, weighs in on a report from CNBC that Amazon will explore entry into the pharmaceutical industry.

  • Cancer data deluge set to move stocks

    CNBC's Meg Tirrell reports on the biotech stocks to watch, including a new player Incyte, as well as Johnson and Johnson's analyst day and Amazon's pharmaceutical break in. "Fast Money Halftime Report" traders and Kevin O'Leary weigh in.

  • J&J CEO: We have to pay attention to out-of-pocket drug costs

    Alex Gorsky, Johnson & Johnson CEO, speaks with CNBC's Meg Tirrell about the company's pharmaceutical business, drug pricing and health-care reform.

  • May 16- Danish drugmaker Novo Nordisk said on Tuesday the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to "a potential conflict of interest." The departure of Mary Szela follows her firm's decision to work on non-alcoholic steatohepatitis, or fatty liver, a Novo company spokeswoman said.

  • Moderna Therapeutics recently revealed that it's working on vaccines for the flu and Zika virus and a therapy for heart failure.

  • Billionaire investor Carl Icahn sold out of the pharmaceutical giant entirely, while Farallon Capital Management LLC, David Tepper's Appaloosa LP and Seth Klarman's Baupost Group LLC were among those trimming their stakes by as much as 32 percent, according to regulatory filings. Paulson& Co Inc and Leon Cooperman's Omega Advisors Inc also pulled back on the...

  • *Sees deal adding 30 cents to adjusted EPS in first year. May 15- Thermo Fisher Scientific Inc said on Monday it would buy Patheon NV, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its offerings in production and services for the biopharma industry. Thermo will also assume $2 billion in net debt, putting the cost of the...

  • Watch short-seller Andrew Left battle the CEO of his latest short position

    Andrew Left, short seller, and Kevin Conroy, Exact Sciences CEO debate a study about Exact Sciences colonoscopy tests.

  • Short seller's bear debate on Exact Sciences

    Andrew Left, activist short seller, discusses the bear debate on Exact Sciences with Kevin Conroy, Exact Sciences CEO.

  • CARLSBAD, Calif. _ Natural Alternatives International Inc. on Monday reported fiscal third-quarter earnings of $745,000. Natural Alternatives shares have declined 14 percent since the beginning of the year. Keywords: Natural Alternatives, Earnings Report.

  • *Patheon shares surge 33.5 pct to $34.70 premarket. Shares of Patheon were up about 33 percent in premarket trading, just shy of the offer price of $35 per share, representing a premium of about 35 percent to Patheon's Friday close. The contract research space is in the midst of a wave of consolidation with INC Research Holdings Inc last week saying it would merge...

  • May 15- Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, said on Monday it would buy Dutch drug ingredients maker Patheon NV for about $5.2 billion in cash. The deal represents a purchase price of about $7.2 billion, which includes the assumption of about $2.0 billion of net debt, the companies said in a statement.

  • LONDON, May 12- AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday. The trial results are a boost for a product the company hopes will become a blockbuster drug with sales in the billions of dollars. "These are highly encouraging...

  • LONDON, May 12- AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday. The trial results are a major boost for a product the company hopes will become a blockbuster drug with sales in the billions of dollars. The drug, which will have the...

  • "The problem has become global," said Suzanne Hill, head of essential medicines at the World Health Organisation. Hill was speaking after a one-day forum on fair pricing sponsored by the U.N. health agency and the Dutch government in Amsterdam. WHO assistant director-general Marie-Paule Kieny said there was agreement that industry needed reasonable returns...

  • The rising price of medicine has led some patients to resort to Facebook for life-saving drugs, NBC News reports.

  • Merck CEO: We're doing the right studies to make KeyTruda broadly available

    Merck CEO Kenneth Frazier speaks to CNBC's Meg Tirrell about the FDA's approval of the company's lung cancer treatment KeyTruda and the general fight against cancer.

  • Full interview with Merck CEO Frazier on FDA's approval of lung cancer drug

    The full interview with Merck CEO Kenneth Frazier.